drugset
drugset / Trial / NCT06785636

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

NCT06785636 ↗

Phase 1/2 Recruiting 120 enrolled Pathos AI, Inc. Duke University · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)

Timeline

Start
2025-02-07
Primary completion
2028-06-30
Completion
2029-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Darolutamide Other / unclassified 600 mg —
Subject Pocenbrodib Small molecule 50 mg Oral
Subject Pocenbrodib Small molecule 125 mg Oral
Subject Pocenbrodib Small molecule 150 mg Oral
Subject Pocenbrodib Small molecule 250 mg Oral

Indications

prostate carcinoma